Shares in Insulet (NSDQ:PODD) soared today after the medical device maker topped sales expectations on Wall Street with its third quarter results.
The Billerica, Mass-based company posted a net loss of -$2.2 million on sales of $121.8 million for the 3 months ended Sept. 30, for bottom-line growth of 38% on sales growth of 28% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Insulet raises full-year sales forecast after Street-beating Q3 appeared first on MassDevice.